Clinical Trials Logo
  1. Home
  2. Hemoglobinuria, Paroxysmal
  3. NCT01224483

Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

Hemoglobinuria, Paroxysmal Clinical Trial

Official title:
Multicenter Retrospective Analysis About the Clinical Characteristics of Korean Patients With PNH

Clinical Trial Summary

Paroxysmal nocturnal hemoglobinuria (PNH) is a hematopoietic stem cell disorder in which unregulated activation of the complement system leads to significant ischemic morbidities with shortened lifespan. Life-threatening thromboembolism (TE) is the most feared complication of PNH, accounting for up to 45% of patient deaths. It is estimated that 40% of PNH patients experience a clinically evident TE and 60% of patients without clinically diagnosed TE demonstrate TE by high-sensitivity MRI, indicating the ongoing thrombotic risk in most patients with PNH. Much of these data come from PNH patients from European descent. To understand the impact of TE in patients with PNH from non-European regions, we performed this study to evaluate the clinical characteristics of Korean patients with PNH.

Clinical Trial Description

To evaluate the clinical characteristics in Korean PNH patients ;

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01224483
Study type Observational
Source Samsung Medical Center
Contact
Status Recruiting
Phase N/A
Start date August 2010
Completion date December 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00997386 - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Phase 2
Completed NCT00122330 - Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Phase 3
Completed NCT00867932 - Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH) Phase 4
Completed NCT00721864 - The Molecular Biology of Paroxysmal Nocturnal Hemoglobinuria (PNH) N/A
Completed NCT00152139 - Stem Cell Transplantation for Patients With Hematologic Malignancies Phase 3
Active, not recruiting NCT01642979 - Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Phase 2
Active, not recruiting NCT01760096 - Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Phase 2
Completed NCT00618969 - Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors Phase 2
Completed NCT00098280 - Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria Phase 3
Completed NCT00122304 - Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab Phase 3
Active, not recruiting NCT00315419 - Identifying Characteristics of Bone Marrow Failure Syndromes N/A
Approved for marketing NCT00438789 - The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol Phase 3